EHR-Native AI: Investing in the New Deterioration Model Frontier

The field for predictive inpatient clinical decision support is getting turned on its head. What was once the turf of specialized third-party vendors is getting eaten by the Electronic Health Record (EHR) giants, who are baking their own proprietary algorithms directly into their platforms. If you’re a health tech VC or a portfolio manager, you have to understand this new competitive reality to find defensible investments and avoid watching your once-promising AI tools become obsolete.

The EHR-Native Advantage: Workflow and Data Moats

This whole realignment comes down to the built-in advantages of EHR-native integration. Companies like Epic Systems and Oracle Health (formerly Cerner) are using their lock-in on hospital workflows to roll out predictive models that are just part of the normal clinical routine. This is way more than a convenience play. It’s changing how these AI tools get built, deployed, and in the end, whether clinicians trust them. A huge piece of this is their immediate access to granular, real-time patient data. EHR systems are the ultimate data moats, collecting every patient history, lab result, med list, and clinical note directly at the point of care. This rich, longitudinal data stream lets the EHR vendors train and retrain their models using a hospital’s own patient data, which could make them much better at fighting algorithmic drift than any outside tool. Plus, native integration completely sidesteps the hell of data interoperability that plagues third-party vendors. All the friction from API calls, data mapping, and keeping data pipelines alive just disappears, which means faster rollouts and lower operational costs for the hospital. The regulatory side is pushing this way, too. The Office of the National Coordinator for Health Information Technology (ONC) Health IT Certification Program, and especially its HTI-1 final rule, is all about transparency for predictive tools. While the rules hit everyone, native EHR algorithms have a much simpler path to proving compliance since they control the data and the model inside their own closed system. For hospitals, this regulatory de-risking makes adoption an easier “yes,” and for investors, it’s a strong signal about the long-term viability of these platforms.

Working through the New Transparency Imperative

The ONC HTI-1 rule says that developers of certified health IT have to give users a lot more information about their predictive algorithms, what they’re for, what data they use, and how well they perform. This is a massive development for anyone trying to evaluate AI health tools. For an EHR-native model, this transparency can be built right into the screen a clinician is already looking at, offering instant insight into how a prediction was made, which data points mattered, and any known blind spots. For instance, a native sepsis prediction model inside an Epic or Oracle Health platform can directly show the specific vital signs, lab values, and chart notes that pushed a patient into the high-risk category, along with confidence scores or other performance metrics. Getting that kind of context inside the existing workflow is what builds trust and lets a doctor make an informed call. Third-party solutions, on the other hand, often have a hard time presenting this information so cleanly, forcing clinicians to jump between different systems or look at clunky, disconnected displays. It might seem like a small difference in user experience, but it can absolutely kill adoption rates and clinical usefulness. Investors must ask every single health AI vendor they vet: how are you meeting the ONC HTI-1 transparency requirements for predictive algorithms?

The Competitive Shift: Hospital Adoption Rates and the Challenge for Third-Party Vendors

The hospital adoption numbers paint a stark picture. Federal data from 2024 shows that hospital adoption of predictive AI built into their EHRs jumped to 71%, a solid increase from 66% in 2023. Breaking it down further for 2024, most hospitals (80%) used predictive AI that came from their EHR developer, while 52% used a third-party tool and 50% used AI they built themselves. This preference for integrated solutions is an existential threat to specialized third-party AI vendors, especially the ones selling “wedge products” that do one thing the EHRs are now starting to do themselves. If a hospital can get a good sepsis prediction model directly from its EHR provider, fully integrated and supported, the argument for paying a separate vendor gets a lot weaker. This trend is forcing third-party companies to find ways to be valuable beyond just having an accurate algorithm.

Identifying Defensible Proprietary Algorithms in an EHR-Dominated Ecosystem

For health tech VCs, the takeaway is simple: you have to invest in proprietary models that solve hard clinical problems that can’t be solved with standard EHR data fields alone. The gold rush of building a predictive model on easily available EHR data and trying to out-compete the EHR vendors is ending fast. The third-party vendors who survive will show clear signs of clinical accountability:

• Deep Clinical Specialization: They’ll have algorithms that depend on highly specialized data types, think advanced imaging, genomic data, or continuous physiological monitoring from wearables, that standard EHR systems don’t routinely capture or analyze. This is how they can build new data moats.
• Novel Algorithmic Approaches: Their solutions will use machine learning architectures or multi-modal data fusion techniques that are genuinely different and produce better predictions or totally new insights, making them hard for an EHR vendor to just copy over a weekend.
• Strong Clinical Evidence and Regulatory Pathway: They need a portfolio of published outcomes studies, including real-world evidence (RWE), that proves their tool makes a real difference for patients. A clear and de-risked regulatory pathway, like a 510(k) clearance or even a De Novo classification for a brand new diagnostic AI, is non-negotiable. Academic validation studies for predictive deterioration models are a good starting point.
• Unique Guardrail Design and Oversight Model: It’s not enough to be transparent. Vendors have to show they have sophisticated guardrails to stop algorithmic bias, ensure fairness across different patient groups, and provide clear ways for humans to step in and override the machine. A rock-solid Quality Management System (QMS) and real adherence to GMLP principles are what build long-term trust and keep regulators happy.
• Reimbursement Clarity: Does the tool have a clear path to getting paid? A strong signal of commercial viability is a plan for reimbursement through existing CPT codes or an innovative payment model like NTAP. Imagine a vendor whose AI analyzes continuous cardiac rhythm data from an external device, fuses it with EHR data, and then predicts a cardiac event with a lead time and accuracy that an EHR-native model just can’t match. That kind of solution, especially if it’s earned a Breakthrough Device Designation and is on a path to Category I CPT codes, is a much more defensible bet than yet another generic inpatient deterioration model. The move toward EHR-native integration of predictive models isn’t just a market trend. It’s rewriting the basic requirements for what makes a reliable AI healthcare vendor. Investors have to do their AI health vendor due diligence with extreme rigor, looking not just at the tech but at its strategic fit in a market that’s consolidating and getting more regulated by the day. The future belongs to proprietary algorithms that create new value through deep specialization and serious clinical accountability, not the ones that just re-package existing EHR data. ***

Methodology and Source Note: We based this analysis on a review of federal regulatory filings, specifically the ONC HTI-1 requirements for predictive decision support, along with public EHR product release notes and roadmaps from the big vendors. Our insights were also shaped by industry reports and discussions at conferences like HIMSS.